Septerna, Inc.

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Biotech IPOs staged a moderate recovery in 2024 but a muted end to the year showed how fragile the market remains for companies looking to launch. Full year data shows 26 companies debuted on US excha

After a brief lull, the trend for biotech companies going public before they have generated clinical data looks well and truly back. South San Francisco-based Septerna has just outlined its plans to r

The tally of biopharmaceutical companies that have gone public in the US in 2024 has now surpassed not only last year’s total but the total from 2022 now that Septerna Inc. has launched its IPO, gross